ライフサイエンスコーパス: short-acting

1 sfer) of high (metabolism-altering) doses of short-acting (0.5 U, once daily, regular, n = 13) or lon

2 cheduled to receive doxorubicin were given a short-acting 5-HT-receptor antagonist and dexamethasone

3 Short-acting 5-HT-receptor antagonists are no better tha

4 ptide levels were significantly reduced with short-acting (-56%, P = 0.01) and long-acting (-67%, P =

5 Short-acting agents (primarily those that increase heart

6 Monitors of depth of anesthesia, ultra-short-acting agents, and combined techniques have minimi

7 ut, at present, the majority of patients use short-acting agents.

8 ated with continuous delivery of levodopa or short-acting agonists, or with the use of long-acting ag

9 dy formation or their release in response to short-acting agonists.

10 suggests that further investigation of oral short-acting alpha4beta integrin blockade therapies is w

11 , 8), 17 (9), 19 (12, 13), or 41 (20) led to short acting analogues.

12 in human airway epithelia but were typically short acting and less effective in CF cultures with prol

13 also noted in the stratification analysis of short-acting and long-acting benzodiazepines.

14 Although short-acting and long-acting inhaled beta(2)-adrenergic

15 Short-acting and low doses of medium-acting muscle relax

16 lable treatments are generally insufficient, short acting, and not without co-morbidities or long-ter

17 nzodiazepine receptor agonist that is also a short acting anesthetic and analgesic drug, can produce

18 We have recently reported that the short-acting anesthetic and analgesic drug midazolam can

19 Despite widespread use of short-acting antagonists for the 5-hydroxytryptamine (5-

20 a(2)-adrenoceptor agonist (salbutamol) and a short-acting anticholinergic (ipratropium bromide), in C

21 Short-acting anticholinergic (SAAC) should be added to S

22 yses and 42 RCTs examined inhaled therapies: short-acting anticholinergics (n = 7), long-acting antic

23 nea management in advanced heart failure, or short-acting antidepressants in terminal illness.

24 teinuria, diabetic status, or greater use of short-acting antihypertensive agents in blacks versus wh

25 her treatment categories, namely as-required short-acting B(2) -agonists (n = 973), ICS monotherapy (

26 Triazolam is a short-acting benzodiazepine that results in phase advanc

27 r oral corticosteroids, >5 prescriptions for short acting beta agonists and more than four visits to

28 , there is an uncertain effect as to whether short-acting beta blockers impact 90-day mortality (RR,

29 on to treat acute asthma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; howeve

30 xperience with Combivent, a combination of a short-acting beta(2)-adrenoceptor agonist (salbutamol) a

31 duces the rate of asthma attacks compared to short-acting beta(2)-agonist (SABA) reliever monotherapy

32 symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but

33 led despite treatment for mild asthma with a short-acting beta(2)-agonist (SABA) with or without a lo

34 acerbation of asthma than as-needed use of a short-acting beta(2)-agonist (SABA); the risk was simila

35 A strong recommendation was made for using a short-acting beta(2)-agonist before exercise in all pati

36 ptoms of EIB despite the administration of a short-acting beta(2)-agonist before exercise, strong rec

37 Recent respiratory symptoms and short-acting beta(2)-agonist use were associated with in

38 Variability in response to short-acting beta(2)-agonists (e.g., albuterol) among pa

39 iated with reductions in the requirement for short-acting beta(2)-agonists (HR = 0.48, 95% CI = 0.43-

40 asthmatics controlled with as needed inhaled short-acting beta(2)-agonists alone, and used bronchoalv

41 hma and who were symptomatic while receiving short-acting beta(2)-agonists alone.

42 sponses encountered with the clinical use of short-acting beta(2)-agonists.

43 Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-do

44 enance inhaled corticosteroids (ICSs) with a short-acting beta-agonist as a separate inhaler used whe

45 -required or "prn") use of a combination ICS/short-acting beta-agonist or ICS/long-acting beta-agonis

46 ints included FEV(1), symptom scores, rescue short-acting beta-agonist use, and exacerbations.

47 l antihistamine, intranasal corticosteroids, short-acting beta-agonist, and inhaled corticosteroids.

48 t infection and less than 2 puffs per day of short-acting beta-agonist; they also experienced a lower

49 lthcare services (51.7%, 511/988) and use of short-acting beta-agonists (55.2%, 545/988) was high.

50 tibiotics (ARR, 0.74 [95% CI, 0.35-1.57]) or short-acting beta-agonists (ARR, 0.95 [95% CI, 0.68-1.33

51 r Asthma (GINA) report no longer recommended short-acting beta-agonists (SABA) monotherapy due to ass

52 Overuse of short-acting beta-agonists (SABAs) could be associated w

53 ountries met the 80% availability target for short-acting beta-agonists (SABAs), three of 48 countrie

54 ng relied on reliever therapy with as-needed short-acting beta-agonists (SABAs), while anti-inflammat

55 Allowed concomitant medications included short-acting beta-agonists and a systemic corticosteroid

56 t visits or hospitalizations, and (3) use of short-acting beta-agonists as quick-relief (sometimes re

57 ed, and few were receiving therapy (4.5% had short-acting beta-agonists).

58 of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, a

59 All trials allowed the use of as-needed short-acting beta-agonists.

60 ta2-adrenergic receptor may not benefit from short-acting beta-agonists.

61 A short-acting beta-antagonist administered immediately af

62 defibrillation, and reperfusion and that the short-acting beta-antagonist esmolol administered at rep

63 thesia monitors and administration of potent short-acting beta-blockers and narcotics to control hemo

64 In patients with septic shock, short-acting beta-blockers may improve survival and redu

65 Short-acting beta-blockers may reduce 28-day mortality (

66 A short-acting beta1-selective adrenergic blocking agent,

67 The short-acting beta1-selective adrenergic blocking agent,

68 re of at least 1 for at least 2 days, rescue short-acting beta2 agonist use for at least 2 days, or n

69 medicines in the previous year were inhaled short-acting beta2 agonists (SABA; range across age grou

70 Cells were cultured in the presence of the short-acting beta2-agonist albuterol, and the long-actin

71 h asthma, 68.4% received prescriptions for a short-acting beta2-agonist and 41.2% for inhaled cortico

72 ong-acting beta2-agonist as maintenance plus short-acting beta2-agonist as reliever.

73 s to assess the bronchodilator response to a short-acting beta2-agonist before and after chronic ther

74 dopamine receptor-beta2-agonist (n = 3), or short-acting beta2-agonist plus ipratropium (n = 3).

75 d-long-acting beta2-agonist maintenance plus short-acting beta2-agonist reliever (hazard ratio, 0.71;

76 orticosteroid-long-acting beta2-agonist plus short-acting beta2-agonist reliever therapy.

77 orticosteroid-long-acting beta2-agonist plus short-acting beta2-agonist reliever.

78 orticosteroid-long-acting beta2-agonist plus short-acting beta2-agonist reliever.

79 SQ-HDM [n = 282]) in addition to ICS and the short-acting beta2-agonist salbutamol.

80 hma being treated at least twice a week with short-acting beta2-agonist, alone or in combination with

81 p 1 (intermittent asthma) therapy (as-needed short-acting beta2-agonists [SABAs] for rescue therapy).

82 Traditional inhaled short-acting beta2-agonists albuterol, fenoterol, and te

83 of aggravating environmental factors, use of short-acting beta2-agonists for rapid relief of symptoms

84 Inhaled short-acting beta2-agonists provide rapid relief of acut

85 rticosteroids (ICSs), leukotriene modifiers, short-acting beta2-agonists, oral corticosteroids, other

86 tient level predictors of poor control were: short acting bronchodilator overuse [2.129 (2.091; 2.164

87 lume in 1 s (FEV1) after administration of a short-acting bronchodilator has been widely used to iden

88 gers and built environment factors on asthma short-acting bronchodilator use.

89 An acute response to a short-acting bronchodilator, especially albuterol, predi

90 idence on the efficacy and safety of inhaled short-acting bronchodilators to treat asthma and wheeze

91 mmatory agents, inhaled corticosteroids, and short-acting bronchodilators) had insufficient evidence,

92 igh-flow oxygen, intravenous fluids, inhaled short-acting bronchodilators, and nebulized adrenaline.

93 ater baseline lung function improvement with short-acting bronchodilators.

94 Short-acting BZDs and Z-drugs were more significantly as

95 .76 [95% CI 0.41-1.43]), whereas patients on short-acting calcium antagonists (n = 27) were at signif

96 Long-acting and short-acting calcium antagonists differ in cardiovascula

97 Short-acting calcium antagonists may increase coronary a

98 Other short-acting calcium antagonists such as diltiazem and v

99 Consistent with earlier findings, the use of short-acting calcium antagonists was associated with inc

100 anti-inflammatory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with h

101 ports add to a growing body of evidence that short-acting calcium-channel blockers, whether used for

102 scular events associated with rapid release, short-acting CAs.

103 Short-acting clonidine should be avoided because of rebo

104 Short-acting contraception methods (eg, oral contracepti

105 tives (intrauterine device and implant), and short-acting contraceptives (injectable and oral contrac

106 ive adenosine receptor agonist WRC-0470 is a short-acting coronary vasodilator with potential utility

107 Eyes that received a short-acting corticosteroid injection before the 0.18-mg

108 The use of short-acting corticosteroid injections before the placem

109 ent use of anti-inflammatory therapy, use of short-acting corticosteroid injections within the 3 mont

110 sociated with greater dosages of levodopa or short-acting DAs.

111 For several short-acting dihydropyridine calcium channel blockers, t

112 ng, but some case-control data, dominated by short-acting dihydropyridines, suggest an increased risk

113 Rather, levodopa or other short-acting dopaminergic drugs induce molecular changes

114 Because HCTZ has been perceived as a short-acting drug, a third comparison with an extended-r

115 This study examined whether the short-acting drug, propofol, could blunt the responses t

116 mmendation might be needed in areas in which short acting drugs are injected.

117 res were cumulated or divided into long- and short-acting drugs.

118 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has fav

119 indicated in men trying to conceive, but new short-acting formulations, including oral testosterone u

120 Using zolpidem (Ambien), a short-acting GABAA agonist hypnotic, we show increased s

121 Therefore zolpidem, a short-acting GABAAR modulator with selectivity for the t

122 increasing use of the medium- (C(2)F(6)) and short-acting gases (SF(6)) or even air.

123 The effects of propofol, a short-acting general anesthetic, upon cell growth and Ca

124 These observations suggest that short-acting GLP-1 agonists may be superior to long-acti

125 The short-acting glucagon-like peptide 1 receptor agonist ex

126 kthrough pain, we present a series of novel, short-acting, high-potency MOR agonist/DOR antagonist li

127 gnificant change in the number of claims for short-acting hormonal contraceptive methods during this

128 ARC), intrauterine devices (IUDs), implants, short-acting hormonal injection, and barrier or other me

129 lined and there was a decrease in the use of short-acting inhaled beta2-stimulants, parenteral aminop

130 lly significant difference in exacerbations, short-acting inhaler fills, or total spending.

131 red (PDC), moderate-to-severe exacerbations, short-acting inhaler fills, total spending, and as an ex

132 Short-acting inhalers for "rescue therapy" were not eval

133 Tirofiban is a highly selective, short-acting inhibitor of fibrinogen binding to platelet

134 metformin (n = 8), insulin glargine (n = 6), short-acting insulin (n = 2), sitagliptin plus metformin

135 o add exogenous bolus insulin therapy, using short-acting insulin analogs or regular insulin.

136 Binding of short-acting insulin and long-acting insulin glargine to

137 od glucose >/=140 mg/dl (treatment group) or short-acting insulin and/or oral antidiabetic agents for

138 on glucose 140 mg/dl with 130 patients given short-acting insulin for fasting glucose 200 mg/dl (cont

139 ed all-cause mortality with long-acting plus short-acting insulin may be explained by noncardiovascul

140 The dosing of short-acting insulin often involves several steps for th

141 tiated at 14 days post-transfer, whereas the short-acting insulin regimen did not retard the onset of

142 g-acting insulin provides basal coverage and short-acting insulin supports glycemic excursions associ

143 Treatment with long-acting plus short-acting insulin was not associated with increased r

144 g-acting insulin alone with long-acting plus short-acting insulin with regard to cardiovascular outco

145 Long-acting insulin alone or with added short-acting insulin within 1 year from the qualifying H

146 ith long-acting insulin (LA group) or adding short-acting insulin within 1 year of the qualifying HbA

147 generally divided into dosing with long- and short-acting insulin, where long-acting insulin provides

148 ISA, LSA, or CRA attributable to the type of short-acting insulin.

149 preparations, combining both long-acting and short-acting insulins, may be used.

150 ested the ability of LY2444296, a selective, short-acting, KOP antagonist, to decrease alcohol self-a

151 acids (EETs) and other epoxy fatty acids are short-acting lipids involved in resolution of inflammati

152 Chloroprocaine is a short-acting local anaesthetic with a rapid onset of act

153 Avaliable data on alternative short-acting local anaesthetics with respect to transien

154 h those induced by procaine (PRO 5 mg/kg), a short-acting local anesthetic with negligible effect on

155 method, with the largest increase in use of short-acting methods at 2.6 (95% CI, 2.3-3.0) percentage

156 contraceptive use has largely been driven by short-acting methods of contraception, despite the high

157 Neither intervention affected the take-up of short-acting methods, such as the pill.

158 ptive methods were more frequently used than short-acting methods.

159 European Trial-has compared carvedilol with short-acting metoprolol tartrate at different dose equiv

160 to CD137 agonism using low-molecular-weight, short-acting molecules with high tumor penetration is a

161 venous administration of an opioid drug (the short-acting mu receptor agonist, remifentanil) acquires

162 s to cocaine or heroin/prescription opioids [short-acting mu-opioid receptor (MOPr) agonists] involve

163 Short-acting mu-opioid receptor (MOR) agonists have long

164 agonists (HR = 0.48, 95% CI = 0.43-0.52) and short-acting muscarinic antagonists (HR = 0.43, 95% CI =

165 Short-acting nifedipine has no role in acute myocardial

166 0.137 mg/kg) linkers were also potent, ultra-short-acting NMBs with good to excellent selectivity ind

167 A single dose of the short-acting NMDA antagonist ketamine produces rapid and

168 A single sub-anesthetic dose of ketamine, a short-acting NMDA receptor blocker, induces a rapid and

169 nkeys for a novel mixed-onium class of ultra-short-acting nondepolarizing tetrahydroisoquinolinium ne

170 Methadone is widely used in treatment of short-acting opiate addiction.

171 ore suggest that prophylaxis with this ultra-short-acting opioid may be advantageous in various clini

172 reased demand elasticity) for the potent and short-acting opioid remifentanil and reduced low-effort

173 ouch upon the possible benefits of the ultra-short acting opioids, and consider the role of alpha-2 a

174 In addition, the use of very short-acting opioids predicted increased pain on POD1, s

175 ng therapeutic hypothermia may be a feasible short-acting option with potential postconditioning effe

176 s and separated by pharmacologic properties (short-acting or long-acting benzodiazepines, Z-drugs).

177 by type of contraception used (long-acting, short-acting, or permanent).

178 In search of novel, potent, selective, and short-acting peptidic V(2)R agonists, we synthesized a s

179 ins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythrop

180 profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for trea

181 r PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors).

182 metabolic stabilization sufficient to obtain short-acting, potent, and selective 11beta-HSD1 inhibito

183 odes can be managed with countermeasures and short-acting pressor agents if necessary.

184 yptamine (DMT) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been inde

185 One short-acting psychedelic is 5-MeO-DMT, which has been as

186 o elucidating how subjective effects of this short-acting psychedelic unfold over time.

187 lopment, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyl

188 Acceptance of ultra-fast, short-acting psychedelics will depend on future randomiz

189 Short-acting pulsatile dopamine agonists are more likely

190 (vials/syringes or pens), therapeutic class (short-acting, rapid-acting, long-acting, intermediate-ac

191 fter abdominal surgery (2 meta-analyses) and short-acting rather than long-acting intraoperative neur

192 study evaluated the efficacy and safety of a short-acting reduced-dose fibrinolytic regimen to promot

193 hat a selective, CNS-penetrant, peripherally short-acting, S1P(1) agonist would show full efficacy in

194 n and reduces cAMP production in response to short-acting (salbutamol) and long-acting (formoterol) b

195 asis by regulating the hindbrain response to short-acting satiety signals.

196 target light sedation when possible, use of short acting sedatives, and avoidance of benzodiazepines

197 Landiolol, a short-acting selective beta1-adrenergic blocker improvin

198 e either a long-acting (several hours) and a short-acting (several minutes) component to the mechanis

199 Drug testing programs must address short-acting stimulants, beta-blockers, and diuretics; t

200 lurea dose, (2) a change from long-acting to short-acting sulfonylurea (glipizide), (3) discontinuati

201 Alfentanil, a rapid and short-acting synthetic analog of fentanyl, appears to of

202 To address the need for short-acting treatments for breakthrough pain, we presen

203 s when needed was considered favourable, but short-acting treatments may not reduce inconvenience com

204 modification led to the identification of a short acting triaminotriazine aniline methoxyamide (comp

205 tery catheters facilitate direct delivery of short acting vasodilator therapy.

206 n be achieved by the airway application of a short-acting vasodilator, such as prostacyclin.

207 ible to hydrolytic clearance and function as short-acting VCMs.

208 ium antagonists, the adjusted risk ratio for short-acting versus long-acting was 8.56 (1.88-38.97), p